By Anna Ferrari ( July 15, 2026, 09:33 GMT | Insight) -- Drugmakers Genentech, Samsung Bioepis, Novartis and Biogen are set to appear before Italian antitrust officials on July 28 for their final defence against allegations they conspired to delay the launch of biosimilar eye drug Byooviz in Italy, MLex has learned. The companies are suspected of seeking to preserve the originator drug Lucentis' monopoly, causing reduced patient access to cheaper biosimilars.Genentech, Samsung Bioepis, Novartis and Biogen are set to appear before Italian antitrust officials on July 28 to present their final arguments in a two-year probe into whether they conspired to delay the launch of biosimilar eye drug Byooviz in Italy, MLex has learned....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.